DAVIS, Calif., June 5, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII) today announced the pricing of 4,500,000 shares of its common stock at $9.50 per share in a follow-on public offering. MBI will sell 3,900,000 shares in the offering; the remaining 600,000 shares will be sold by an existing stockholder, Syngenta Ventures Pte. LTD. In addition, the underwriters have a 30-day option to purchase up to 675,000 additional shares of common stock from MBI. MBI will not receive the proceeds from the sale of shares by the selling stockholder.
MBI currently intends to use the net proceeds it receives from the proposed offering for working capital required to accelerate the commercial adoption of its existing products, to accelerate the development of its product pipeline and to expand its network of strategic relationships, for capital expenditures, including to purchase equipment to facilitate its research and development efforts and to accelerate completion of the manufacturing facility it acquired in July 2012, and for general corporate purposes, such as acquiring complementary businesses, products or technologies.
Jefferies LLC and Piper Jaffray & Co. are acting as lead joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated, Robert W. Baird & Co. Incorporated and Roth Capital Partners, LLC are co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 5, 2014. This offering is being made by MBI and the selling stockholder only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com, and from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by calling (800) 747-3924 or by emailing prospectus@pjc.com.
This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.